TransCode Therapeutics's total assets for Q1 2026 were $157.16M, a decrease of -3.22% from the previous quarter. RNAZ total liabilities were $12.64M for the fiscal quarter, a -91.69% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.